Patrick Tremblay

Biography

Patrick joined the Caprion team in 2011. He is a biopharmaceutical and investment executive with broad expertise in R&D and business development. He is leading the corporate strategies and the development of innovative diagnostics based on proteomic discoveries made at Caprion for indications such as cancer, as well as metabolic and infectious diseases. Prior to joining Caprion, Patrick has worked with Pappas Ventures, a US-based venture capital firm that guided the development of more than 50 life science companies in therapeutics, diagnostics, medical devices and personalized medicine. He held positions as Vice-President of R&D at BioAxone and as Director of Pharmacology at Neurochem where he developed neuroprotective and neuroregenerative drugs for Alzheimer’s disease and spinal cord injury. He was also Assistant Professor in Neurology at the University of California in San Francisco where he worked on neurodegenerative diseases induced by prions and was part of the Nobel Laureate Team of Stanley Prusiner, Medicine and Physiology (1997). Patrick has been involved in many innovative life science initiatives. He is one of the co-founders of the Personalized Medicine Partnership for Cancer and was intimately involved in the creation and financing of the new Neomed Institute. In recent years, he has held numerous advisory positions with diverse organizations such as the Campus des Technologies de la Santé, Quebec Consortium for Drug Discovery, Centre of Excellence for Commercialization and Research of the Montreal Neurological Institute and at Pharmacology Institute of Sherbrooke University. He is presently a member of the Board of Directors of Univalor. Patrick holds a B.Sc. degree in Microbiology and Immunology from McGill University and a Ph.D. in Molecular Biology from the University of Montreal. He has also completed post-doctoral studies at the Max Planck Institute for Biophysical Chemistry in Germany. Patrick joined the Caprion team in 2011. He is a biopharmaceutical and investment executive with broad expertise in R&D and business development. He is leading the corporate strategies and the development of innovative diagnostics based on proteomic discoveries made at Caprion for indications such as cancer, as well as metabolic and infectious diseases. Prior to joining Caprion, Patrick has worked with Pappas Ventures, a US-based venture capital firm that guided the development of more than 50 life science companies in therapeutics, diagnostics, medical devices and personalized medicine. He held positions as Vice-President of R&D at BioAxone and as Director of Pharmacology at Neurochem where he developed neuroprotective and neuroregenerative drugs for Alzheimer’s disease and spinal cord injury. He was also Assistant Professor in Neurology at the University of California in San Francisco where he worked on neurodegenerative diseases induced by prions and was part of the Nobel Laureate Team of Stanley Prusiner, Medicine and Physiology (1997). Patrick has been involved in many innovative life science initiatives. He is one of the co-founders of the Personalized Medicine Partnership for Cancer and was intimately involved in the creation and financing of the new Neomed Institute. In recent years, he has held numerous advisory positions with diverse organizations such as the Campus des Technologies de la Santé, Quebec Consortium for Drug Discovery, Centre of Excellence for Commercialization and Research of the Montreal Neurological Institute and at Pharmacology Institute of Sherbrooke University. He is presently a member of the Board of Directors of Univalor. Patrick holds a B.Sc. degree in Microbiology and Immunology from McGill University and a Ph.D. in Molecular Biology from the University of Montreal. He has also completed post-doctoral studies at the Max Planck Institute for Biophysical Chemistry in Germany.

Research Interest

Clinical Pharmacy  Pharmaceutical Administration Medicinal Chemistry